|Bid||31.20 x 800|
|Ask||32.30 x 1100|
|Day's Range||31.49 - 33.39|
|52 Week Range||19.38 - 87.24|
|Beta (5Y Monthly)||2.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.21|
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
Shares of Axsome Therapeutics (NASDAQ: AXSM) lost 9.75% of their value through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. The biotech's shares are currently well off of their 52-week highs due to a regulatory delay for its experimental major depressive disorder drug AXS-05. What's important to understand is that this regulatory hiccup reportedly centers around two issues with the company's analytical methods in the Chemistry, Manufacturing, and Controls section of the New Drug Application submitted to the Food and Drug Administration (FDA).
All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.